Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematology Am Soc Hematol Educ Program 2016 Dec 02;2016(1):10-15
Date
12/04/2016Pubmed ID
27913456Pubmed Central ID
PMC6142484DOI
10.1182/asheducation-2016.1.10Scopus ID
2-s2.0-85021848968 (requires institutional sign-in at Scopus site) 41 CitationsAbstract
Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia (AML), which presents with a distinct coagulopathy. Therapeutic advances have made APL one of the true success stories in oncology, transforming this once lethal disease into the most curable form of AML. For many patients, cure will now be achieved without the use of chemotherapy. It is hoped that limiting chemotherapy will reduce mortality even further, particularly among more vulnerable older adults whose survival lagged behind that of younger patients. It should be noted that early death persists in patients with APL and continues to negatively affect survival. Further, among survivors treated with chemotherapy or even arsenic trioxide (ATO), there remains the potential for long-term toxicities that must be monitored. Understanding the management of these issues is an important complement to ensure maximal survival for patients with APL.
Author List
Abedin S, Altman JKAuthor
Sameem Abedin MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAge Factors
Arsenicals
Disease-Free Survival
Humans
Leukemia, Promyelocytic, Acute
Oxides
Survival Rate
